Voraxaze carboxypeptidase G2 regulatory update

The FDA granted Orphan Drug designation for Voraxaze as a rescue therapy to treat patients at risk of methotrexate toxicity during cancer therapy. Voraxaze, which has completed Phase III testing, rece...